Publication:
Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.

Simple item page
dc.contributor.authorMoreso, Francesc
dc.contributor.authorCrespo, Marta
dc.contributor.authorRuiz, Juan C
dc.contributor.authorTorres, Armando
dc.contributor.authorGutierrez-Dalmau, Alex
dc.contributor.authorOsuna, Antonio
dc.contributor.authorPerelló, Manel
dc.contributor.authorPascual, Julio
dc.contributor.authorTorres, Irina B
dc.contributor.authorRedondo-Pachón, Dolores
dc.contributor.authorRodrigo, Emilio
dc.contributor.authorLopez-Hoyos, Marcos
dc.contributor.authorSeron, Daniel
dc.date.accessioned2023-01-25T10:00:37Z
dc.date.available2023-01-25T10:00:37Z
dc.date.issued2017-10-24
dc.description.abstractThere are no approved treatments for chronic antibody mediated rejection (ABMR). We conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate efficacy and safety of intravenous immunoglobulins (IVIG) combined with rituximab (RTX) (EudraCT 2010-023746-67). Patients with transplant glomerulopathy and anti-HLA donor-specific antibodies (DSA) were eligible. Patients with estimated glomerular filtration rate (eGFR)
dc.identifier.doi10.1111/ajt.14520
dc.identifier.essn1600-6143
dc.identifier.pmid28949089
dc.identifier.unpaywallURLhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ajt.14520
dc.identifier.urihttp://hdl.handle.net/10668/11613
dc.issue.number4
dc.journal.titleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
dc.journal.titleabbreviationAm J Transplant
dc.language.isoen
dc.organizationHospital Universitario Virgen de las Nieves
dc.page.number927-935
dc.pubmedtypeClinical Trial, Phase II
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeRandomized Controlled Trial
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subjectclinical research/practice
dc.subjectclinical trial
dc.subjectkidney (allograft) function/dysfunction
dc.subjectkidney transplantation/nephrology
dc.subjectpathology/histopathology
dc.subjectrejection: antibody-mediated (ABMR)
dc.subject.meshAdult
dc.subject.meshAllografts
dc.subject.meshChronic Disease
dc.subject.meshDouble-Blind Method
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshGlomerular Filtration Rate
dc.subject.meshGraft Rejection
dc.subject.meshGraft Survival
dc.subject.meshHLA Antigens
dc.subject.meshHumans
dc.subject.meshImmunoglobulins, Intravenous
dc.subject.meshImmunologic Factors
dc.subject.meshIsoantibodies
dc.subject.meshKidney Failure, Chronic
dc.subject.meshKidney Function Tests
dc.subject.meshKidney Transplantation
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPostoperative Complications
dc.subject.meshPrognosis
dc.subject.meshProspective Studies
dc.subject.meshRisk Factors
dc.subject.meshRituximab
dc.subject.meshTissue Donors
dc.titleTreatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number18
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Virgen de las Nieves

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía